Phenelzine Epinephrine

Monoamine oxidase inhibitors. The monoamine oxidase inhibitors (MAOIs) inhibit the intracellular catabolic enzyme monoamine oxidase. There are two types of monoamine oxidase MAO-A and MAO-B, both of which metabolize tyramine and dopamine. In addition, MAO-A preferentially metabolizes norepinephrine, epinephrine, and serotonin, and MAO-B preferentially metabolizes phenylethylamine (an endogenous amphetamine-like substance) and N-methylhistamine (Ernst, 1996). Some MAOIs are selective for A or B and some are nonselective (mixed). In addition, irreversible MAOIs (e.g., phenelzine, tranylcypromine) are more susceptible to the cheese effect than are the reversible agents (e.g., moclobemide). 

Monoamine oxidase inhibitors (MAOI) Neurotransmitters norepinephrine, dopamine, epinephrine, and serotonin are inactive by the enzyme monoamine oxidase. MAOI inhibits monoamine oxidase, resulting in a rise in the levels of these neurotransmitters. MAOI are isocarboxazid (Marplan), phenelzine sulfate (Nardil), and tranylcypromine sulfate (Parnate). 

Clinically important, potentially hazardous interactions with amprenavir, clonidine, ephedra, epinephrine, eucalyptus, guanethidine, iobenguane, isocarboxazid, linezolid, MAO inhibitors, paroxetine, phenelzine, quinolones, sparfloxacin, St John s wort, tranylcypromine... 

---